{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:10:38Z","timestamp":1790993438771,"version":"4.1.0"},"reference-count":70,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Vitiligo is characterized by the development of depigmented macules and patches. Autoimmunity has been established as a factor in disease pathogenesis, leading to utilization of immunosuppressive agents. Topical immunosuppressants are commonly used; however, this treatment modality is often cumbersome and inefficient, as many patients have active disease with extensive body surface area involvement. Prompt and aggressive treatment of vitiligo is important, as this may prevent progression and improve quality of life. To meet these challenges and improve patient outcomes, interest in systemic therapies has grown. Currently, oral therapies are rarely prescribed, likely due to concerns with systemic side effects and unclear efficacy. This article provides a brief overview on the use of systemic agents in treating vitiligo in order to provide additional therapeutic options to clinicians.<\/jats:p>","DOI":"10.1111\/ijd.16114","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T06:19:42Z","timestamp":1644301182000},"page":"279-289","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Systemic therapies in vitiligo: a review"],"prefix":"10.1111","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5100-064X","authenticated-orcid":false,"given":"Sakeena","family":"Fatima","sequence":"first","affiliation":[{"name":"Department of Dermatology University Hospitals Cleveland Medical Center  Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tazeen","family":"Abbas","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine Staten Island University Hospital  Staten Island NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggi A.","family":"Refat","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Massachusetts Medical School  Worcester MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Harris","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Massachusetts Medical School  Worcester MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry W.","family":"Lim","sequence":"additional","affiliation":[{"name":"Multicultural Dermatology Center, Department of Dermatology Henry Ford Hospital  Detroit MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltefat H.","family":"Hamzavi","sequence":"additional","affiliation":[{"name":"Multicultural Dermatology Center, Department of Dermatology Henry Ford Hospital  Detroit MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasneem F.","family":"Mohammad","sequence":"additional","affiliation":[{"name":"Multicultural Dermatology Center, Department of Dermatology Henry Ford Hospital  Detroit MI USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.5005\/jp\/books\/12775_3"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.07.039"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1615\/JEnvironPatholToxicolOncol.2015014168"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S6496"},{"key":"e_1_2_10_6_1","volume-title":"Pigmentary disorders: a comprehensive compendium","author":"Lahiri K","year":"2014"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1993.tb02754.x"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.113475"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.2310\/7750.2013.12053"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1999.00623.x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI16432"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546630600791442"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.025"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.07.059"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38258"},{"key":"e_1_2_10_16_1","unstructured":"US Food and Drug AdministrationPrescribing information: JAKAFI (ruxolitinib) (Reference ID: 4546367).2020[cited 2020 21 October]; Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202192Orig1s019Rpllbl.pdf."},{"key":"e_1_2_10_17_1","unstructured":"US Food and Drug AdministrationPrescribing information: XELJANZ (tofacitinib) (Reference ID: 4269956).2018[cited 2020 21 October]; Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s018lbl.pdf."},{"key":"e_1_2_10_18_1","volume-title":"Micromedex","author":"IBM Corporation","year":"2020"},{"key":"e_1_2_10_19_1","volume-title":"Micromedex","author":"IBM Corporation","year":"2020"},{"key":"e_1_2_10_20_1","unstructured":"US Food and Drug AdministrationPrescribing information: RAYOS (prednisone) (Reference ID: 3165107).2012[cited 2020 21 October]; Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/202020s000lbl.pdf."},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1191\/0961203305LU2109OA"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.08.049"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-020-02108-8"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1159\/000433424"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.8.729"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2012.12.003"},{"issue":"6","key":"e_1_2_10_27_1","first-page":"309","article-title":"Unstable vitiligo responding to methotrexate","volume":"64","author":"Sandra A","year":"1998","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153740"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.02.063"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20142573"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1990.01670270071012"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijdvl.IJDVL_656_18"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15033"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.02.062"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007811"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14671"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.09.016"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.073"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.02.049"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30609-7"},{"issue":"21","key":"e_1_2_10_41_1","first-page":"1043","article-title":"Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: descriptive subgroup analyses from a phase 2, randomized, double\u2010blind trial","volume":"0190","author":"Hamzavi I","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_10_42_1","unstructured":"Incyte Corporation.A study of INCB018424 phosphate cream in subjects with vitiligo (NCT03099304).2017[cited 2020 October 22]; Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03099304."},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12921"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1520"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aam7710"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.05.043"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/283617"},{"issue":"1","key":"e_1_2_10_48_1","first-page":"9","article-title":"Minocycline protects melanocytes against H2O2\u2010induced cell death via JNK and p38 MAPK pathways","volume":"22","author":"Song X","year":"2008","journal-title":"Int J Mol Med"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2010.01328.x"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.148562"},{"issue":"8","key":"e_1_2_10_51_1","first-page":"CD002086","article-title":"Minocycline for acne vulgaris: efficacy and safety","volume":"2012","author":"Garner SE","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2007.02514.x"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.3109\/14764172.2015.1114646"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.3889\/oamjms.2018.048"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2003.01207.x"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6882-11-21"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2005.12.006"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.02132.x"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14776"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09252.x"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.4103\/2279-042X.108375"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2008.03660.x"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1729952"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1001\/2013.jamadermatol.386"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.1875"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/dat.20536"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.03.027"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-79"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2007.00137.x"},{"issue":"4","key":"e_1_2_10_71_1","first-page":"220","article-title":"Pharmaceutical approval update","volume":"41","author":"Fellner C.","year":"2016","journal-title":"P T."}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.16114","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.16114","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.16114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T18:08:58Z","timestamp":1692382138000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.16114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,7]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1111\/ijd.16114"],"URL":"https:\/\/doi.org\/10.1111\/ijd.16114","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,7]]},"assertion":[{"value":"2021-06-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}